Premium
CD38 expression enhances sensitivity of lymphoma T and B cell lines to biochemical and receptor‐mediated apoptosis
Author(s) -
Gregorini Armando,
Tomasetti Marco,
Cinti Cristina,
Colomba Daniela,
Colomba Stella
Publication year - 2006
Publication title -
cell biology international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.932
H-Index - 77
eISSN - 1095-8355
pISSN - 1065-6995
DOI - 10.1016/j.cellbi.2006.05.004
Subject(s) - cd38 , apoptosis , jurkat cells , annexin , k562 cells , lymphoma , microbiology and biotechnology , cell culture , cancer research , leukemia , biology , chemistry , immunology , t cell , biochemistry , stem cell , genetics , immune system , cd34
CD38 has been widely characterised both as an ectoenzyme and as a receptor. In the present paper, we investigated the role of CD38 as possible modulator of apoptosis. CD38‐positive (CD38 + ) and negative (CD38 − ) fractions, obtained by sorting CD38 + cells from lymphoma T (Jurkat) and lymphoma B (Raji) and by transfecting lymphoma LG14 and myeloid leukemia K562 cell lines, were used. Cellular subpopulations were exposed to different triggers (H 2 O 2 , UV‐B, α‐TOS and hrTRAIL) and the extent of apoptosis was determined by Annexin V‐FITC/PI assay. Our data showed that, in lymphoma cells, propensity to apoptosis was significantly linked to CD38 expression and that, remarkably, such response was independent of the nature of the trigger used. Inhibition of CD38 expression by antisense oligonucleotides treatment resulted in CD38‐silenced fractions which were as prone to apoptosis as CD38 − ones. Notably, susceptibility of K562 to apoptosis‐inducing challenges was not affected by CD38 expression.